Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Biocon has gotten the Establishment Inspection Report (EIR) from the U. S. Food and Drug Administration (FDA) for the Pre-Approval and GMP examination of its Small Molecules API Manufacturing Facility at Biocon Park SEZ, Bommansandra, Bengaluru, led between 20 January and 24 January 2020. At the finish of the review the office had given a Form 483, with five perceptions, which are being tended to by the Company. The EIR has been shut with a VAI arrangement for the perceptions.